netFormulary North Central London NHS
Joint Formulary  
 Search
 Formulary Chapter 4: Central nervous system - Full Chapter
Chapter Links...
 Details...
04.10.01  Expand sub section  Alcohol dependence
Acamprosate
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
AAAAAAAA

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Requires psychiatrist approval. For use in accordance with NICE CG115.
  • UCLH approvals:
  • WH approvals:
    • Not applicable
 
   
Disulfiram
View adult BNF View SPC online View childrens BNF
Formulary
AAAAAAAA

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Nil
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
 
   
Nalmefene
View adult BNF View SPC online View childrens BNF
Formulary

Secondary care notes

  • NMUH approvals:
    • This medicine has a positive NICE TA but service is not provided at NMUH.
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Not applicable
 
Link  NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
   
Naltrexone
(alcohol dependence)
View adult BNF View SPC online View childrens BNF
Formulary
AAAAAAAA

Secondary care notes

  • NMUH approvals:
    • Not applicable
  • RFL approvals:
    • Not applicable
  • RNOH approvals:
    • Not applicable
  • UCLH approvals:
  • WH approvals:
    • Nil
 
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing. 

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.  

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary